Fully compliant EU-CTD dossier for Lenalidomide

Lenalidomide Dossier ready for out-licensing

Lenalidomide Dossier

Midas Pharma has developed together with its development partner Grindeks JSC a fully compliant EU-CTD dossier for Lenalidomide (2,5/5/7,5/10/15/20/25 mg) which is ready for out-licensing!

First Marketing Authorizations based on our dossier have been granted in European countries.

The fact that the manufacturing site for the product is located in Latvia, being a white spot country, allows for day 1 launches upon SPC-expiry in June 2022.

We offer attractive and competitive prices along with small volumes per SKU.

Midas/Grindeks have filed different patent applications for Lenalidomide. We expect that most generic product developments that may be marketed from June 2022 onwards to bear a considerable risk of infringing our patents.

For further information please contact us.

Your Contact

Jonas Ulrich

Jonas Ulrich

Business Development
Senior Manager

Midas Pharma GmbH
Rheinstr. 49
55218 Ingelheim

Telephone: +49 6132 990-211
  • Disclaimer

    “The exploitation, including the development, sale and offer for sale of above product and related processes is performed by Midas only in those territories where permissible by applicable patent law in particular, but not limited to EC Directive 2001/83 EC, Article 10, as amended by EC Directive 2004/27 EC . This promotion, therefore, does not and shall not constitute an offer for sale for products and processes in territories where an offer for sale or sale is not permissible by law. Midas expressly disclaims any liability for damages resulting from or arising out of the use of such products and related processes for purposes other than research and development in compliance with applicable laws.”

Share this page